0
October 6, 1934, Vol 103, No. 14 >
ARTICLE | October 6, 1934

ERYSIPELAS AND PRODIGIOSUS TOXINS (COLEY)

JAMA. 1934;103(14):1070-1071. doi:10.1001/jama.1934.02750400038015.
Text Size: A A A
Published online
Article
References

In this issue of The Journal (p. 1067) is reported the reacceptance for inclusion in New and Nonofficial Remedies of Erysipelas and Prodigiosus Toxins (Coley), long, albeit somewhat sporadically, employed in the treatment of selected cases of inoperable bone sarcoma. Although Coley first employed a vaccine of Streptococcus erysipelatis in inoperable malignant conditions as early as 1893, a satisfactory explanation of the therapeutic mechanism has not yet been advanced. The use of the product, like that of nonspecific proteins, has rested on an empirical basis supported solely by clinical observations of occasional cases of inoperable malignant disease which have exhibited spontaneous regression following fulminating attacks of acute infectious diseases, particularly erysipelas. Sir James Paget is said to have been the first to record such an occurrence.

Jacobsen1 in a recent paper advances a theory based on related observations of the alleged increased incidence of cancer and the noteworthy present-day

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Letters

Submit a Letter
CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Clear Answers | Save For Later
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs

More Listings at
JAMACareerCenter.com >

© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems